470 related articles for article (PubMed ID: 28814433)
1. Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
Raghavan S; Mehta P; Ward MR; Bregenzer ME; Fleck EMA; Tan L; McLean K; Buckanovich RJ; Mehta G
Clin Cancer Res; 2017 Nov; 23(22):6934-6945. PubMed ID: 28814433
[No Abstract] [Full Text] [Related]
2. Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance.
Ward Rashidi MR; Mehta P; Bregenzer M; Raghavan S; Fleck EM; Horst EN; Harissa Z; Ravikumar V; Brady S; Bild A; Rao A; Buckanovich RJ; Mehta G
Neoplasia; 2019 Aug; 21(8):822-836. PubMed ID: 31299607
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism.
Liao J; Qian F; Tchabo N; Mhawech-Fauceglia P; Beck A; Qian Z; Wang X; Huss WJ; Lele SB; Morrison CD; Odunsi K
PLoS One; 2014; 9(1):e84941. PubMed ID: 24409314
[TBL] [Abstract][Full Text] [Related]
4. CD10
Ffrench B; Gasch C; Hokamp K; Spillane C; Blackshields G; Mahgoub TM; Bates M; Kehoe L; Mooney A; Doyle R; Doyle B; O'Donnell D; Gleeson N; Hennessy BT; Stordal B; O'Riain C; Lambkin H; O'Toole S; O'Leary JJ; Gallagher MF
Cell Death Dis; 2017 Oct; 8(10):e3128. PubMed ID: 29048400
[TBL] [Abstract][Full Text] [Related]
5. In Ovarian Cancer Multicellular Spheroids, Platelet Releasate Promotes Growth, Expansion of ALDH+ and CD133+ Cancer Stem Cells, and Protection against the Cytotoxic Effects of Cisplatin, Carboplatin and Paclitaxel.
Casagrande N; Borghese C; Agostini F; Durante C; Mazzucato M; Colombatti A; Aldinucci D
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809553
[TBL] [Abstract][Full Text] [Related]
6. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.
He M; Wang D; Zou D; Wang C; Lopes-Bastos B; Jiang WG; Chester J; Zhou Q; Cai J
Oncotarget; 2016 Dec; 7(52):86374-86387. PubMed ID: 27863439
[TBL] [Abstract][Full Text] [Related]
7. Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties.
Hirst J; Pathak HB; Hyter S; Pessetto ZY; Ly T; Graw S; Koestler DC; Krieg AJ; Roby KF; Godwin AK
Cancer Res; 2018 Aug; 78(15):4370-4385. PubMed ID: 29891506
[TBL] [Abstract][Full Text] [Related]
8. Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy.
Nishikawa S; Konno M; Hamabe A; Hasegawa S; Kano Y; Ohta K; Fukusumi T; Sakai D; Kudo T; Haraguchi N; Satoh T; Takiguchi S; Mori M; Doki Y; Ishii H
Int J Oncol; 2013 Apr; 42(4):1437-42. PubMed ID: 23440340
[TBL] [Abstract][Full Text] [Related]
9. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.
Casagrande N; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Clin Cancer Res; 2014 Nov; 20(21):5496-506. PubMed ID: 25231401
[TBL] [Abstract][Full Text] [Related]
10. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
11. Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian cancer stem cells.
Kim DK; Seo EJ; Choi EJ; Lee SI; Kwon YW; Jang IH; Kim SC; Kim KH; Suh DS; Seong-Jang K; Lee SC; Kim JH
Exp Mol Med; 2016 Aug; 48(8):e255. PubMed ID: 27561949
[TBL] [Abstract][Full Text] [Related]
12. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian Tumors.
Chowanadisai W; Messerli SM; Miller DH; Medina JE; Hamilton JW; Messerli MA; Brodsky AS
PLoS One; 2016; 11(3):e0151089. PubMed ID: 26986722
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation.
Guo F; Yang Z; Kulbe H; Albers AE; Sehouli J; Kaufmann AM
Biomed Pharmacother; 2019 Oct; 118():109371. PubMed ID: 31545281
[TBL] [Abstract][Full Text] [Related]
15. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
Abubaker K; Latifi A; Luwor R; Nazaretian S; Zhu H; Quinn MA; Thompson EW; Findlay JK; Ahmed N
Mol Cancer; 2013 Mar; 12():24. PubMed ID: 23537295
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.
Casagrande N; De Paoli M; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Gynecol Oncol; 2013 Dec; 131(3):744-52. PubMed ID: 24029417
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
18. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM
Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799
[TBL] [Abstract][Full Text] [Related]
19. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
20. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
